Skip to Content


Emily A. Largent and Holly Fernandez Lynch (Former Executive Director)
JAMA Oncology
April 19, 2018

Read the Full Article

From the article:

Shortfalls in clinical trial recruitment and retention constitute a major obstacle to scientific advancement. One means of increasing patient participation rates is to reduce associated financial burdens. In several states, efforts are under way to achieve this goal for patients in cancer clinical trials through legislation explicitly allowing reimbursement of certain clinical trial–related expenses. Although laudable, these efforts fall far short. Financial barriers to participation exist beyond the confines of oncology, and singling out reimbursement fails to take advantage of other ethically permissible functions of offering payment, including compensating for research-related burden and incentivizing participation.

Read more here!

Read the Full Article

Tags

clinical research   health law policy   holly fernandez lynch   public health